These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21170268)

  • 1. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
    Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
    Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
    Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
    Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.
    Banerjee A; Wu ZS; Qian P; Kang J; Pandey V; Liu DX; Zhu T; Lobie PE
    Breast Cancer Res; 2011; 13(6):R112. PubMed ID: 22060274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
    Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
    Taylor KJ; Sims AH; Liang L; Faratian D; Muir M; Walker G; Kuske B; Dixon JM; Cameron DA; Harrison DJ; Langdon SP
    Breast Cancer Res; 2010; 12(3):R39. PubMed ID: 20569502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
    Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
    Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
    Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
    Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
    Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells.
    Amiry N; Kong X; Muniraj N; Kannan N; Grandison PM; Lin J; Yang Y; Vouyovitch CM; Borges S; Perry JK; Mertani HC; Zhu T; Liu D; Lobie PE
    Endocrinology; 2009 Oct; 150(10):4473-83. PubMed ID: 19589871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
    Xie D; Miller CW; O'Kelly J; Nakachi K; Sakashita A; Said JW; Gornbein J; Koeffler HP
    J Biol Chem; 2001 Apr; 276(17):14187-94. PubMed ID: 11297518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
    Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.